Infections in a pediatric patient cohort with acute lymphoblastic leukemia during the entire course of treatment
โ Scribed by Katerina Katsimpardi; Vassilios Papadakis; Anastasia Pangalis; Agapi Parcharidou; John P. Panagiotou; Michael Soutis; Evangelos Papandreou; Sophia Polychronopoulou; Stavros Haidas
- Publisher
- Springer-Verlag
- Year
- 2005
- Tongue
- English
- Weight
- 124 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0941-4355
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
The biologic impact and clinical toxicity of Corynebacterium parvum administered at a dose of 5 mg/M2 by intravenous or subcutaneous routes were evaluated in 18 children receiving combination chemotherapy for maintenance of acute lymphoblastic leukemia (ALL) in remission. Several nonspecific immunol
## BACKGROUND. The purpose of the current study was to evaluate the cytogenetic features of the hypodiploid leukemic cells of pediatric patients with this rare subgroup of acute lymphoblastic leukemia (ALL). In addition, the authors determined whether subdivision of the hypodiploid category served
Results in 258 children with acute lymphoblastic leukemia (ALL) treated in the Czech Republic between 1979 and 1983 according to in-house protocols demonstrated a dismal outcome. The complete remission (CR) rate was 82%, 3-year event free survival (EFS) 30% and overall survival 44%. The Czech Workin
## Abstract 6โMercaptopurine (6MP) is an essential anticancer drug used in the treatment of childhood acute lymphoblastic leukemia (ALL). Thiopurine methyltransferase (TPMT) polymorphisms are the major determinants of interindividual differences in the severe toxicity or efficacy of 6MP. Four varia